公司简介
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascul...
关联新闻
- Heart Disease, a Historic Strength for Big Pharma, Becomes a Weakness
Heart disease remains humanity's top killer, yet for drugmakers and Wall Street, it is becoming one of the hardest places to make money.
- Jim Cramer says investors are too focused on AI stocks. Here's where he says to look instead
CNBC's Jim Cramer said investors should look beyond the AI data-center trade as compelling opportunities emerge in other areas of the market. He highlighted aerospace, fintech, health care and energy ...
- Disappointing Clinical Trial Results Are Dragging Novartis, Amgen and the Dow Lower Tuesday
U.S.-listed shares of Novartis are slumping Tuesday morning following disappointing clinical trial results from the Swiss drugmaker.
- Cholesterol drug setback casts doubt over multibillion-dollar race
Novartis' pelacarsen failed to reduce cardiovascular events despite lowering the harmful cholesterol Lp(a). The setback raises uncertainty for rival experimental Lp(a) drugs from Amgen and Eli Lilly.
- UK regulator suspends Amgen's Tavneos for new patients over unreliable data
Britain's medicines regulator on Tuesday suspended the use and sale of Amgen's rare-disease drug, Tavneos, to new patients, saying the main study supporting its approval was unreliable.
- Trump administration to announce drug pricing deals
U.S. President Donald Trump is expected to announce a new round of drug-pricing agreements on Monday, a White House official said, part of a push to make healthcare more affordable for Americans.
- White House to announce new drug pricing deals with biotechs, Bloomberg News reports
U.S. President Donald Trump's administration is planning to announce a new round of drug-pricing agreements with midsize biotech companies on Monday, Bloomberg News reported on Wednesday, c...